Effect of the Surgery Type, Mastectomy vs. Breast Conserving Surgery, on Outcomes of Patients With Locally Advanced Breast Cancer Receiving Neoadjuvant Therapy

Negar Mashoori (1), Sanaz Zand (2), Ryan Nazemian (3), Ahmad Kaviani (4)
(1) Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran. AND Research Department, Kaviani Breast Disease Institute (KBDI), Tehran, Iran., Iran, Islamic Republic of,
(2) Research Department, Kaviani Breast Disease Institute(KBDI), Tehran, Iran., Iran, Islamic Republic of,
(3) Department of Anesthesiology, University Hospitals, Cleveland Medical Center, USA. AND Institute for Transformative Molecular Medicine, Case Western Reserve University, USA., Iran, Islamic Republic of,
(4) Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran. AND Research Department, Kaviani Breast Disease Institute (KBDI), Tehran, Iran., Iran, Islamic Republic of
https://doi.org/10.19187/abc.201744129-135

Article Sidebar

Issue
Vol 4, No 4: November 2017
Submitted
July 23, 2017
Published
December 10, 2017
Keywords:
    Breast cancer, Neoadjuvant chemotherapy, Mastectomy, Breast-conserving surgery, Outcome, Survival
PDF

Abstract

Background: Breast cancer is the most prevalent site-specific cancer and one of the most frequent causes of cancer death in women worldwide. Neoadjuvant chemotherapy, along with surgical treatment—breast conserving surgery (BCS) or mastectomy—is an important part of treatment for locally advanced breast cancer. As BCS is preferred to mastectomy in terms of cosmetic, quality-of-life, and functional outcomes, it would be the preferred treatment for locally advanced breast cancer (LABC), if its oncological safety is confirmed.
Methods: In this study, we retrospectively compared the oncologic outcomes of post-neoadjuvant chemotherapy BCS with mastectomy in 202 patients with LABC.
Results: There were no significant differences between BCS and mastectomy regarding overall survival, local recurrence, contralateral breast cancer, and distant metastasis.
Conclusions: Our study showed that post-neoadjuvant chemotherapy BCS is an oncologically safe surgical treatment in LABC and that BCS can be considered as an acceptable treatment in selected patients with LABC.

Full text article

Generated from XML file

Authors

Negar Mashoori
Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran. AND Research Department, Kaviani Breast Disease Institute (KBDI), Tehran, Iran.
Sanaz Zand
Research Department, Kaviani Breast Disease Institute(KBDI), Tehran, Iran.
Ryan Nazemian
Department of Anesthesiology, University Hospitals, Cleveland Medical Center, USA. AND Institute for Transformative Molecular Medicine, Case Western Reserve University, USA.
Ahmad Kaviani
Department of Surgery, Tehran University of Medical Sciences, Tehran, Iran. AND Research Department, Kaviani Breast Disease Institute (KBDI), Tehran, Iran.
akaviani@tums.ac.ir (Primary Contact)
1.
Mashoori N, Zand S, Nazemian R, Kaviani A. Effect of the Surgery Type, Mastectomy vs. Breast Conserving Surgery, on Outcomes of Patients With Locally Advanced Breast Cancer Receiving Neoadjuvant Therapy. Arch Breast Cancer [Internet]. 2017 Dec. 10 [cited 2024 Jul. 16];4(4):129-35. Available from: https://archbreastcancer.com/index.php/abc/article/view/150
Download Citation
Endnote/Zotero/Mendeley (RIS)

Copyright (c) 2017 Archives of Breast Cancer

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.

Article Details

Most read articles by the same author(s)

<< < 1 2 3 4 5